Fluticasone-formoterol clinical trials
How each study uses fluticasone-formoterol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Mundipharma Research Limited (6) · SkyePharma AG (1)
Often tested with
Tested in the same studies.
Fluticasone-Salmeterol Drug Combination (1) · Fluticasone (1)
Studies
Open first, then newest update. How each study uses fluticasone-formoterol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPDCompletedPhase 3Mundipharma Research LimitedNCT01946620Written as FlutiformHow we know
- Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible AsthmaCompletedPhase 3Mundipharma Research LimitedNCT00476073Written as FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)How we know
- Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric PatientsCompletedPhase 3Mundipharma Research LimitedNCT01511367Written as FlutiformHow we know
- Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible AsthmaCompletedPhase 3Mundipharma Research LimitedNCT01099722Written as FlutiformHow we know
- Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With AsthmaCompletedPhase 3Mundipharma Research LimitedNCT00475813Written as FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)How we know
- An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible AsthmaCompletedPhase 3Mundipharma Research LimitedNCT00563056Written as FlutiformHow we know
- A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005CompletedPhase 3SkyePharma AGNCT00747318Written as SKP FlutiForm HFA pMDIHow we know